The Conversation (0)
Teligent Announces FDA Approval of Desonide Ointment
Mar. 14, 2019 08:58AM PST
Pharmaceutical InvestingTeligent (NASDAQ:TLGT) has announced it has received approval from the FDA for its abbreviated new drug application (ANDA) of desonide ointment, 0.05 percent. As quoted in the press release: is is Teligent’s second approval of 2019, and its thirty-fourth approval from its internally-developed pipeline of topical generic pharmaceutical medicines. Based on recent IQVIA data from …
Teligent (NASDAQ:TLGT) has announced it has received approval from the FDA for its abbreviated new drug application (ANDA) of desonide ointment, 0.05 percent.
As quoted in the press release:
is is Teligent’s second approval of 2019, and its thirty-fourth approval from its internally-developed pipeline of topical generic pharmaceutical medicines.
Based on recent IQVIA data from January 2019, the total addressable market for this product is approximately $12.5 million.
“This first-review-cycle approval again shows the strength of Teligent’s internal R&D capabilities as we continue to build our portfolio and realize the value of our pipeline,’’ commented Jason Grenfell-Gardner, President and CEO of the Company.
Mr. Grenfell-Gardner continued, “We now have thirty-nine topical generic pharmaceutical products in the US portfolio, in addition to our four US injectable products.”
